ClinicalTrials.gg
CompletedNCT06783621US HarmonyUpdated May 22, 2026

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

A Phase 4 interventional study of OnabotulinumtoxinA and JUVÉDERM in Facial Contouring, sponsored by AbbVie. Completed at 10 sites in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
22 Years to 65 Years
Sex
All
01

Study summary

A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.

02

Conditions studied

  • Facial Contouring

Keywords

  • Facial Contouring
  • OnabotulinumtoxinA
  • JUVEDERM Products
  • KYBELLA
  • CoolSculpting Elite
  • SkinMedica
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Applies to All Participants:

  • Must meet at least 1 of the following criteria for BOTOX UFL treatment per investigator's assessment:

    • Moderate or severe on Allergan Glabellar Line Severity Scale at maximum furrow
    • Moderate or severe on Forehead Line Severity Scale at maximum brow elevation and Moderate or Severe on Allergan Glabellar Line Severity Scale at maximum furrow
    • Moderate or severe on Lateral Canthal Line Severity Scale at maximum contraction (identical severity on both sides)
  • Must meet at least 3 of the following criteria for treatment in the face with at least 2 JUVÉDERM products, per investigator's assessment:

    • Moderate or severe on Allergan Loss of Jawline Definition Scale
    • Moderate or severe on Allergan Chin Retrusion Scale
    • Moderate, significant, or severe on Midface Volume Deficit Scale
    • Moderate or severe on Nasolabial Fold Severity Scale
    • Moderate or severe for both eyes on Allergan Infraorbital Hollows Scale
    • Minimal, mild, or moderate on 5-point Allergan Lip Fullness Scale
    • Moderate or severe on Allergan Cheek Smoothness Scale
    • Minimal, moderate, or severe on Allergan Temple Hollowing Scale

Applies only to participants who will be treated for submental fullness:

- Moderate or severe on the Clinician-reported Submental Fat Rating Scale (for KYBELLA treatment) or Moderate, severe, or extreme (For CoolSculpting Elite treatment) per investigator's assessment.

Exclusion criteria

Exclusion Criteria:

  • History of medical condition that may put the subject at increased medical risk with exposure to OnabotulinumtoxinA, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
  • History of or allergy to any botulinum toxin serotype, Streptococcal protein, lidocaine (or any amide-based anesthetics), HA products, any other or constituents of the study drug, device, SkinMedica products and/or other products in the same class.
  • Marked facial asymmetry (e.g., asymmetry in eyebrow and/or eyelid position, asymmetrical smile or significant asymmetry in the lower face), facial nerve palsy, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart.
  • Previous plastic surgery, tissue grafting, permanent facial implants (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene), or tissue augmentation with silicone, fat, or other permanent dermal fillers of the face and/or neck or plan to undergo any of these procedures at any time during the study.
  • Prior exposure to botulinum toxin of any serotype to any part of the body within 6 months prior to screening.
  • Prior treatment with non-permanent soft tissue fillers or fat-reducing injectables in the face or neck within 12 months prior to screening.
  • Prior treatment with energy-based devices (e.g., intense pulsed light, Clear + Brilliant®, monopolar radiofrequency, microfocused ultrasound, etc.,) or other noninvasive fat reduction procedure and/or skin-tightening laser treatments in the face or neck within 6 months prior to screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Cohort 1: Open-Label Combination Treatments

    All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).

    Drug: OnabotulinumtoxinA · Device: JUVÉDERM · Device: CoolSculpting Elite System · Other: SkinMedica Products · Drug: KYBELLA

  • Experimental
    Cohort 2: Open-Label Combination Treatments

    All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).

    Drug: OnabotulinumtoxinA · Device: JUVÉDERM · Other: SkinMedica Products

Interventions

  • Intramuscular Injections

  • DeviceJUVÉDERM

    Injections

    Also known as: VOLUX XC, VOLUMA XC, VOLLURE XC, VOLBELLA XC, SKINVIVE, ULTRA PLUS XC, ULTRA XC

  • DeviceCoolSculpting Elite System

    CoolSculpting Elite Applicator

  • OtherSkinMedica Products

    Skincare Product

  • Injections

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Satisfaction with Facial Appearance Scale at the Final Visit

    The FACE-Q Satisfaction with Facial Appearance is a validated questionnaire that asks participants to report their level of satisfaction with the appearance of their face.

    Time frame: Up to approximately 284 days

Secondary outcomes

  1. Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Psychological Function Scale at the Final Visit

    The FACE-Q Psychological Function is a validated questionnaire that asks participants to report their level of satisfaction with psychological function.

    Time frame: Up to approximately 284 days

  2. Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Social Function Scale at the Final Visit

    The FACE-Q Social Function Scale is a validated questionnaire that asks participants to report their level of satisfaction with social function.

    Time frame: Up to approximately 284 days

  3. Change from Baseline in the Participant's Rasch-Transformed Score of the SKIN-Q Scale at the Final Visit

    The SKIN-Q Scale is a validated questionnaire that asks participants to report their level of satisfaction with skin quality.

    Time frame: Up to approximately 284 days

07

Study locations

10 sites
  • Marcus Facial Plastic Surgery /ID# 270408
    Redondo Beach, California 90277, United States
  • Pacific Clinical Innovations /ID# 270414
    Vista, California 92083-6030, United States
  • Center for Dermatology and Dermatologic Surgery /ID# 270390
    Washington D.C., District of Columbia 20037-1495, United States
  • Skin Research Institute LLC /ID# 270410
    Coral Gables, Florida 33146-1837, United States
  • DelRicht Research - Prytania Street - New Orleans 308 /ID# 270425
    New Orleans, Louisiana 70115, United States
  • Boyd /Id# 270509
    Birmingham, Michigan 48009-6301, United States
  • Luxurgery /ID# 270430
    New York, New York 10021, United States
  • Bellaire Dermatology Associates /ID# 270429
    Bellaire, Texas 77401, United States
  • Integrated Aesthetics /ID# 270399
    Spring, Texas 77388, United States
  • SkinDC /ID# 270411
    Arlington, Virginia 22209, United States
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 20, 2025
StartActual
Jan 16, 2025
Primary completionActual
Mar 20, 2026
CompletionActual
Mar 20, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06783621
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jan 16, 2025
Primary completion
Mar 20, 2026
Completion
Mar 20, 2026
Last update
May 22, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion